ストックスクリーナーアプリを入手
3.15
2.17%
-0.07
アフターアワーズ：
3.15
前日終値:
$3.22
開ける：
$3.18
24時間の取引高:
933.80K
Relative Volume:
1.33
時価総額：
$316.03M
収益：
-
当期純損益:
$-299.80M
株価収益率:
-0.2599
EPS:
-12.1221
ネットキャッシュフロー:
$-217.49M
1週間 パフォーマンス:
-2.48%
1か月 パフォーマンス:
-28.89%
6か月 パフォーマンス:
-20.85%
1年 パフォーマンス:
-55.76%
1日の値動き範囲:
$3.105
$3.25
1週間の範囲:
$3.105
$3.60
52週間の値動き範囲:
$3.105
$8.885
Acelyrin Inc Stock (SLRN) Company Profile
SLRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
3.15 | 316.03M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-09-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-30 | 開始されました | Jefferies | Buy |
| 2023-05-30 | 開始されました | Morgan Stanley | Overweight |
| 2023-05-30 | 開始されました | Piper Sandler | Overweight |
| 2023-05-30 | 開始されました | TD Cowen | Outperform |
すべてを表示
Acelyrin Inc (SLRN) 最新ニュース
Fmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Fmr LLC - MarketBeat
Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
SLRN stock touches 52-week low at $3.18 amid market challenges - Investing.com Australia
Acelyrin (NASDAQ:SLRN) Earns “Neutral” Rating from HC Wainwright - Defense World
Acelyrin stock drops as izokibep trial fails to meet primary endpoint - MSN
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data - BioSpace
Acelyrin's (SLRN) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Acelyrin shares retain neutral rating despite trial setback By Investing.com - Investing.com UK
Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks
Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha
Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch
Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch
Acelyrin announces izokibep trial did not meet primary endpoint - TipRanks
ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times
Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha
Polar Asset Management Partners Inc. Sells 150,700 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Jacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acuta Capital Partners LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Analysts - MarketBeat
HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey
TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada
Acelyrin discloses ValenzaBio acquisition financials - Investing.com India
TD Cowen maintains Buy rating on Acelyrin shares - Investing.com
T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com
Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada
ACELYRIN, INC. Advances Key Drug Developments - TipRanks
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times
ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan
(SLRN) Investment Analysis and Advice - Stock Traders Daily
Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times
ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Acelyrin Inc (SLRN) 財務データ
収益
当期純利益
現金流量
EPS
Acelyrin Inc (SLRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
| Lin Shao-Lee | Chief Executive Officer |
Feb 20 '24 |
Sale |
7.60 |
15,701 |
119,403 |
1,587,335 |
| Lin Shao-Lee | Chief Executive Officer |
Jan 02 '24 |
Sale |
7.41 |
10,691 |
79,188 |
1,603,036 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):